文献速递精神分裂症与精神病性障碍

抗精神病药联合处方的患病率、相关因素、耐受性相关结局与疗效相关结局:系统综述与Meta分析

Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2024-11-12

该系统综述与Meta分析检索MEDLINE和Embase(2009年1月1日至2024年4月30日),纳入517项研究、599个时间点、4 459 149人,估计抗精神病药联合处方总体患病率为24.8%(95%CI 22.9-26.7),并从1970年至2023年显著上升(β=0.019,95%CI 0.009-0.029;p=0.0002);与单药治疗相比,联合处方与复发、精神科住院、全局功能更差及更多不良事件相关。

要点

  • 抗精神病药联合处方总体患病率24.8%,精神分裂症谱系障碍者达33.2%,痴呆者5.2%。
  • 患病率从1970年至2023年显著上升(β=0.019,95%CI 0.009-0.029;p=0.0002)。
  • 与单药治疗相比,联合处方与复发(RR 1.42)、住院(RR 1.24)及更多不良事件相关。

核心结论

  • 过去50年全球抗精神病药联合处方患病率上升,在精神分裂症谱系障碍患者中尤其高。
  • 与单药治疗相比,联合处方与更严重的疾病严重度和更差的结局相关,但并未解决这些问题。
  • 联合处方与更高的副作用负担相关,包括全因死亡风险。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE和Embase(2009年1月1日至2024年4月30日)及两项既往系统综述中2009年5月1日前的相关研究。
  • 纳入报告精神疾病人群或使用抗精神病药人群中抗精神病药联合处方患病率的任何原始研究(观察性和干预性),不限年龄或诊断。
  • 共分析517项研究、599个个体时间点,报告4 459 149人(平均年龄39.5岁,范围6.4-86.3)。
  • 采用随机效应Meta分析估计汇总患病率,并用亚组和混合效应Meta回归分析相关因素。
  • 研究已在PROSPERO注册(CRD42022329953)。

主要发现

  • 总体24.8%(95%CI 22.9-26.7)的人群接受抗精神病药联合处方,精神分裂症谱系障碍者为33.2%(30.6-36.0),痴呆者为5.2%(4.0-6.8)。
  • 联合处方患病率按地区从北美15.4%(95%CI 12.9-18.2)到非洲38.6%(27.7-50.6)不等。
  • 总体患病率从1970年至2023年显著上升(β=0.019,95%CI 0.009-0.029;p=0.0002)。
  • 成人高于儿童青少年(27.4%,95%CI 25.2-29.8 vs 7.0%,4.7-10.3;p<0.0001),住院患者高于门诊患者(31.4%,27.9-35.2 vs 19.9%,16.8-23.3;p<0.0001)。
  • 与单药治疗相比,联合处方与复发(RR 1.42,95%CI 1.04-1.93;p=0.028)、精神科住院(RR 1.24,95%CI 1.12-1.38;p<0.0001)、全局功能更差(SMD -0.31,95%CI -0.44至-0.19;p<0.0001)相关。

局限性

  • 原文报告数据中性别和族裔信息报告不频繁。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotic polypharmacy remains a clinical reality, despite an increased risk of adverse events and little evidence of additional efficacy compared with antipsychotic monotherapy. In this systematic review and meta-analysis, we aimed to provide a comprehensive assessment of antipsychotic polypharmacy prevalence, trends, and correlates across mental disorders. METHODS: We searched MEDLINE and Embase from Jan 1, 2009 to April 30, 2024, for any original study (observational and interventional) reporting antipsychotic polypharmacy prevalence in populations with mental disorders or use of antipsychotics, regardless of age or diagnosis. Relevant studies before May 1, 2009, were identified from two previous systematic reviews of antipsychotic polypharmacy prevalence. Pooled antipsychotic polypharmacy prevalence was estimated using random-effects meta-analysis. Using subgroup and mixed-effects meta-regression analyses, we sought to identify relevant correlates of antipsychotic polypharmacy. People with lived experience were not involved in the project. This review is registered with PROSPERO (CRD42022329953). FINDINGS: We analysed 517 studies with 599 individual timepoints reporting on 4 459 149 individuals (mean age 39·5 years [range 6·4-86·3]; data on sex and ethnicity were infrequently reported). Most studies included patients with schizophrenia spectrum disorders (SSDs; k=270, 52%). Overall, 24·8% (95% CI 22·9-26·7) of the populations received antipsychotic polypharmacy, ranging from 33·2% (30·6-36·0) in people with SSDs to 5·2% (4·0-6·8) in people with dementia. Antipsychotic polypharmacy prevalence varied by region from 15·4% (95% CI 12·9-18·2) in North America to 38·6% (27·7-50·6) in Africa. Overall antipsychotic polypharmacy prevalence increased significantly from 1970 to 2023 (β=0·019, 95% CI 0·009-0·029; p=0·0002) and was higher in adults than in children and adolescents (27·4%, 95% CI 25·2-29·8 vs 7·0%, 4·7-10·3; p<0·0001) and among inpatients than among outpatients (31·4%, 27·9-35·2 vs 19·9%, 16·8-23·3; p<0·0001). Compared with antipsychotic monotherapy, antipsychotic polypharmacy was associated with an increased risk of relapse (relative risk [RR] 1·42, 95% CI 1·04-1·93; p=0·028), psychiatric hospitalisation (1·24, 1·12-1·38; p<0·0001), worse global functioning (standardised mean difference [SMD] -0·31, 95% CI -0·44 to -0·19; p<0·0001), and more adverse events, including extrapyramidal symptoms (RR 1·63, 95% CI 1·13-2·36; p=0·0098), dystonia (5·91, 1·20-29·17; p=0·029), anticholinergic use (1·91, 1·55-2·35; p<0·0001), higher side-effect scores (SMD 0·33, 95% CI 0·24-0·42; p<0·0001), longer corrected QT interval (0·24, 0·23-0·26; p<0·0001), and greater all-cause mortality risk (RR 1·19, 95% CI 1·00-1·41; p=0·047). INTERPRETATION: The prevalence of antipsychotic polypharmacy has increased globally over the past 50 years and is particularly high in patients with SSDs. Prescription of antipsychotic polypharmacy is associated with greater illness severity and poorer outcomes than is antipsychotic monopharmacy but does not resolve these issues. Furthermore, antipsychotic polypharmacy is associated with higher side-effect burden, including all-cause mortality. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Højlund M, Köhler-Forsberg O, Gregersen AT, et al. Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis. Lancet Psychiatry. 2024. PMID: 39547246. doi:10.1016/S2215-0366(24)00314-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。